Aurobindo Pharma Ltd banner

Aurobindo Pharma Ltd
NSE:AUROPHARMA

Watchlist Manager
Aurobindo Pharma Ltd Logo
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Watchlist
Price: 1 231 INR 0.84% Market Closed
Market Cap: ₹715B

Relative Value

The Relative Value of one AUROPHARMA stock under the Base Case scenario is hidden INR. Compared to the current market price of 1 231 INR, Aurobindo Pharma Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AUROPHARMA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

AUROPHARMA Competitors Multiples
Aurobindo Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Aurobindo Pharma Ltd
NSE:AUROPHARMA
715B INR 2.1 20.3 9.4 12.5
US
Eli Lilly and Co
NYSE:LLY
966.3B USD 14.9 47 31.7 33.7
US
Johnson & Johnson
NYSE:JNJ
586.6B USD 6.2 22 15.2 18.7
CH
Roche Holding AG
SIX:ROG
291.9B CHF 4.8 31.2 13.1 15.3
CH
Novartis AG
SIX:NOVN
248.6B CHF 5.7 23 14.2 18.2
UK
AstraZeneca PLC
LSE:AZN
237.5B GBP 5.5 31.5 17.4 24.5
US
Merck & Co Inc
NYSE:MRK
298.1B USD 4.6 16.4 10.3 12
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.4 7.7 9
US
Pfizer Inc
NYSE:PFE
154.7B USD 2.5 19.9 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
123B USD 2.6 17.5 7.3 9
P/E Multiple
Earnings Growth PEG
IN
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Average P/E: 23.9
20.3
13%
1.6
US
Eli Lilly and Co
NYSE:LLY
47
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
31.2
29%
1.1
CH
Novartis AG
SIX:NOVN
23
15%
1.5
UK
AstraZeneca PLC
LSE:AZN
31.5
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.4
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.4
7%
1.5
US
Pfizer Inc
NYSE:PFE
19.9
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.5
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Average EV/EBITDA: 43.5
9.4
9%
1
US
Eli Lilly and Co
NYSE:LLY
31.7
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
CH
Novartis AG
SIX:NOVN
14.2
9%
1.6
UK
AstraZeneca PLC
LSE:AZN
17.4
11%
1.6
US
Merck & Co Inc
NYSE:MRK
10.3
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.7
7%
1.1
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-12%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett